<p><strong>与全球知名的医疗设备工程和制造组织 Syrma Johari Medtech 的合作，扩大了 INBS 的全球制造能力，加强了供应链的韧性，并支持预计在计划进入美国市场之前，毛利率改善约 20 个百分点</strong></p>
<p>纽约，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Intelligent Bio Solutions Inc.（纳斯达克：INBS）（&#34;INBS&#34;或&#34;公司&#34;），一家提供智能、快速、非侵入性检测解决方案的医疗技术公司，今天宣布与 Syrma Johari MedTech Ltd.（“Syrma Johari”）建立新的战略制造合作关系。Syrma Johari 是一家全球知名的医疗设备工程和制造组织，拥有超过 45 年的经验，旨在支持和扩大其智能指纹药物筛查阅读器的生产。此次合作预计还将支持长期的利润改善。</p>
<p>预计此次合作将为公司带来显著的运营和财务收益。INBS 预计年生产成本节省超过 40%，这将转化为毛利率预计改善约 20 个百分点，相较于其之前的制造安排。此外，Syrma Johari 的制造能力约为 INBS 当前能力的四倍，使公司能够高效支持预期的需求，随着商业运营的扩大而增长。</p>
<p>此次合作加强了 INBS 的全球制造战略，减少了对单一供应商的依赖，并为其供应链构建了更大的韧性。它进一步扩大了产能，确保了连续性，并在公司为 2026 年计划进入美国市场和多个地区的预期未来需求做准备时创造了灵活性。</p>
<p>Syrma Johari 在受监管的医疗技术设备的设计、工程和生产方面拥有深厚且经过验证的经验。它在印度、欧洲和美国运营 14 个制造地点和四个设计与创新中心，合计厂房面积超过 110 万平方英尺。Syrma Johari 完全符合 ISO 13485、MDSAP、FDA、TUV SUD 和 GMP 标准，确保医疗设备制造的世界级合规性和质量。</p>
<p>Syrma Johari 的规模、垂直整合和以出口为导向的运营模式使其能够高质量生产，同时在采购、工具、测试和物流方面创造效率。它在电子、机械组装、PCB 制造、功能测试和洁净室工艺方面的专业知识使其能够以始终如一的高标准生产 INBS 的指纹药物筛查阅读器，同时随着时间的推移提供成本优势。随着 Syrma Johari 准备在 2026 年 1 月在印度开设新的医疗级塑料制造设施，它进一步扩展了其能力，以满足日益增长的全球需求，并为国际客户提供在亚洲战略性位置的可靠制造替代方案。</p>
<p>Syrma Johari 广泛的监管和质量保证能力进一步与 INBS 的全球扩张计划相一致。它提供端到端的质量体系、监管文档支持和合规流程，旨在满足包括美国、欧洲、加拿大、英国和关键亚太市场在内的主要司法管辖区的要求。这种深厚的经验将支持 INBS 在继续推进其监管路径的同时，为全球商业活动的增加做好准备。</p>
<p><em>“与 Syrma Johari 的合作是我们业务的一个战略性重要里程碑，” Intelligent Bio Solutions 全球质量与运营副总裁 Callistus Sequeira 表示。</em> <em>“它的全球足迹、制造卓越和在受监管医疗设备方面的成功记录使其成为我们扩大药物筛查阅读器生产的杰出合作伙伴。这次合作加强了我们的供应链，支持未来的增长，并增强了我们向全球客户提供可靠、高质量产品的能力。”</em></p>
<p>Syrma Johari 的领导层表达了类似的看法，指出此次合作反映了在创新、质量和长期愿景方面的强大一致性，并表示很高兴能够支持 INBS 扩大具有全球潜力的颠覆性药物筛查技术。</p>
<p><em>“与 Intelligent Bio Solutions 的合作是一个令人兴奋的机会，可以将我们的工程实力、制造规模和质量体系应用于具有全球潜力的突破性技术，” Syrma Johari MedTech Ltd.国际销售与业务发展负责人 Pankaj Wadke 表示。“在 Syrma Johari MedTech，我们致力于推动创新解决方案，产生有意义的影响，我们期待支持 INBS 扩大对这一颠覆性非侵入性药物筛查平台的访问。”</em></p>
<p><strong>关于 Intelligent Bio Solutions Inc.</strong></p>
<p>Intelligent Bio Solutions Inc.（纳斯达克：INBS）是一家提供智能、快速、非侵入性检测解决方案的医疗技术公司。公司相信，其智能指纹药物筛查系统将通过指纹汗液分析彻底改变便携式检测，具有在其他领域更广泛应用的潜力。该系统设计为卫生且具有成本效益，能够筛查工作场所常见药物的近期使用情况，包括鸦片类药物、可卡因、甲基苯丙胺和大麻。样本收集只需几秒钟，结果在十分钟内即可得出，这项技术将成为安全关键行业雇主的宝贵工具。公司当前在美国以外的客户群体包括建筑、制造和工程、运输和物流公司、矿业、药物治疗组织和法医。</p>
<p>欲了解更多信息，请访问：https://ibs.inc/</p>
<p><strong>关于 Syrma Johari MedTech</strong></p>
<p>Syrma Johari MedTech 是一家全球医疗设备工程和制造公司，拥有超过 45 年的经验，提供先进的电子产品、医疗设备和生命科学设备。该公司在印度、美国和欧洲运营 14 个制造设施和多个研发中心，提供涵盖设计、工程、原型制作、PCBA、组装、供应链和质量保证与法规支持的端到端服务。Syrma Johari 持有 ISO 13485:2016、MDSAP、FDA、GMP 和 TUV SUD 认证，并在全球范围内商业化了超过 245 种医疗产品。</p>
<p>欲了解更多信息，请访问：https://syrmajoharimedtech.com/</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告中的某些声明属于 1933 年证券法第 27A 条、1934 年证券交易法第 21E 条和 1995 年私人证券诉讼改革法的前瞻性声明，涉及风险和不确定性。本新闻稿中的前瞻性声明包括但不限于关于 Intelligent Bio Solutions Inc.成功开发和商业化其药物和诊断测试、从其合作伙伴关系和合作中实现商业利益，以及获得监管批准或许可等方面的声明。尽管 Intelligent Bio Solutions Inc.认为这些前瞻性声明中反映的预期在发布时是合理的，但实际结果可能与这些声明所表达或暗示的结果有重大差异。Intelligent Bio Solutions Inc.试图通过术语来识别前瞻性声明，包括 “相信”、“估计”、“预期”、“期待”、“计划”、“项目”、“打算”、“潜在”、“可能”、“可以”、“或许”、“将”、“应该” 和 “大约” 等，或其他传达未来事件或结果不确定性的词汇来识别这些前瞻性声明。这些声明仅为预测，涉及已知和未知的风险、不确定性和其他因素，包括在 Intelligent Bio Solutions 向美国证券交易委员会的公开文件中描述的因素。本公告中包含的任何前瞻性声明仅在发布之日有效。Intelligent Bio Solutions 没有义务更新本公告中包含的任何前瞻性声明，以反映其日期之后发生的事件或情况，或反映意外事件的发生。</p>
<p><strong>公司联系方式</strong></p>
<p>Intelligent Bio Solutions Inc.</p>
<p>info@ibs.inc</p>
<p><strong>投资者及媒体联系方式</strong></p>
<p>Valter Pinto，董事总经理</p>
<p>KCSA 战略传播</p>
<p>电话：（212）896-1254</p>
<p>INBS@kcsa.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EUTVNaU0zTXpRd05EVTNJekl4T0RrMU5qVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EUTVNaU0zTXpRd05EVTNJekl4T0RrMU5qVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODUyNGZlMGYtNWI0NS00MzlhLThkOGMtZDZhNTY5YTMzZWRiLTEyMDExMTgtMjAyNS0xMi0zMS1lbg==/tiny/Intelligent-Bio-Solutions-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODUyNGZlMGYtNWI0NS00MzlhLThkOGMtZDZhNTY5YTMzZWRiLTEyMDExMTgtMjAyNS0xMi0zMS1lbg==/tiny/Intelligent-Bio-Solutions-Inc-.png"/></p>

INBS

<p>Intelligent Bio Solutions Inc. (INBS) 宣布与 Syrma Johari MedTech 建立战略制造合作伙伴关系，以增强其全球生产能力，并将毛利率提高约 20 个百分点。此次合作旨在扩大 Intelligent Fingerprinting Drug Screening Reader 的生产，预计年生产成本节省将超过 40%。Syrma Johari 的广泛制造能力和合规性将支持 INBS 的扩展计划，特别是在其为 2026 年进入美国市场做准备时。该合作关系预计将增强 INBS 的供应链韧性和运营效率</p>

<p><strong>Partnership with Syrma Johari Medtech, a globally recognized medical device engineering and manufacturing organization, expands INBS’ global manufacturing capacity, strengthens supply-chain resilience, and supports an expected improvement of approximately 20 percentage points in gross margin ahead of planned U.S. market entry</strong></p>
<div class="lb-trans"><p><strong>与全球知名的医疗设备工程和制造组织 Syrma Johari Medtech 的合作，扩大了 INBS 的全球制造能力，加强了供应链的韧性，并支持预计在计划进入美国市场之前，毛利率改善约 20 个百分点</strong></p>
</div><p>NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (&#34;INBS&#34; or the &#34;Company&#34;), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”), a globally recognized medical device engineering and manufacturing organization with over 45 years of experience, to support and scale the production of its Intelligent Fingerprinting Drug Screening Reader. The collaboration is also expected to support long-term margin improvement.</p>
<div class="lb-trans"><p>纽约，2025 年 12 月 31 日（GLOBE NEWSWIRE）-- Intelligent Bio Solutions Inc.（纳斯达克：INBS）（&#34;INBS&#34;或&#34;公司&#34;），一家提供智能、快速、非侵入性检测解决方案的医疗技术公司，今天宣布与 Syrma Johari MedTech Ltd.（“Syrma Johari”）建立新的战略制造合作关系。Syrma Johari 是一家全球知名的医疗设备工程和制造组织，拥有超过 45 年的经验，旨在支持和扩大其智能指纹药物筛查阅读器的生产。此次合作预计还将支持长期的利润改善。</p>
</div><p>The partnership is expected to deliver significant operational and financial benefits for the Company. INBS anticipates annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin compared with its previous manufacturing arrangement. Additionally, Syrma Johari’s manufacturing capacity is approximately four times INBS’ current capacity, positioning the Company to efficiently support anticipated demand as it scales commercial operations.</p>
<div class="lb-trans"><p>预计此次合作将为公司带来显著的运营和财务收益。INBS 预计年生产成本节省超过 40%，这将转化为毛利率预计改善约 20 个百分点，相较于其之前的制造安排。此外，Syrma Johari 的制造能力约为 INBS 当前能力的四倍，使公司能够高效支持预期的需求，随着商业运营的扩大而增长。</p>
</div><p>The partnership strengthens INBS' global manufacturing strategy, reducing reliance on a single supplier and building greater resilience into its supply chain. It further broadens capacity, ensures continuity, and creates flexibility as the Company prepares for anticipated future demand across multiple regions and planned U.S. market entry in 2026.</p>
<div class="lb-trans"><p>此次合作加强了 INBS 的全球制造战略，减少了对单一供应商的依赖，并为其供应链构建了更大的韧性。它进一步扩大了产能，确保了连续性，并在公司为 2026 年计划进入美国市场和多个地区的预期未来需求做准备时创造了灵活性。</p>
</div><p>Syrma Johari brings a deep and proven track record in the design, engineering, and production of regulated medical technology devices. It operates 14 manufacturing locations and four design and innovation centres across India, Europe, and the United States, with a combined plant area of over 1.1 million sq. ft. Syrma Johari is fully certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring world-class compliance and quality in medical device manufacturing.</p>
<div class="lb-trans"><p>Syrma Johari 在受监管的医疗技术设备的设计、工程和生产方面拥有深厚且经过验证的经验。它在印度、欧洲和美国运营 14 个制造地点和四个设计与创新中心，合计厂房面积超过 110 万平方英尺。Syrma Johari 完全符合 ISO 13485、MDSAP、FDA、TUV SUD 和 GMP 标准，确保医疗设备制造的世界级合规性和质量。</p>
</div><p>Syrma Johari’s scale, vertical integration, and export-oriented operating model enable high-quality production while creating efficiencies in sourcing, tooling, testing, and logistics. Its expertise in electronics, mechanical assembly, PCB manufacturing, functional testing, and clean-room processes positions them to produce INBS' fingerprint drug-screening reader to a consistently high standard, while delivering cost advantages over time. As Syrma Johari prepares to open its new medical-grade plastics manufacturing facility in India in January 2026, it is further expanding its capabilities to meet growing global demand and provide international clients with a strategically located, reliable manufacturing alternative in Asia.</p>
<div class="lb-trans"><p>Syrma Johari 的规模、垂直整合和以出口为导向的运营模式使其能够高质量生产，同时在采购、工具、测试和物流方面创造效率。它在电子、机械组装、PCB 制造、功能测试和洁净室工艺方面的专业知识使其能够以始终如一的高标准生产 INBS 的指纹药物筛查阅读器，同时随着时间的推移提供成本优势。随着 Syrma Johari 准备在 2026 年 1 月在印度开设新的医疗级塑料制造设施，它进一步扩展了其能力，以满足日益增长的全球需求，并为国际客户提供在亚洲战略性位置的可靠制造替代方案。</p>
</div><p>Syrma Johari’s extensive regulatory and quality-assurance capabilities further align with INBS' global expansion plans. It provides end-to-end quality systems, regulatory documentation support, and compliance processes designed to meet the requirements of major jurisdictions, including the U.S., Europe, Canada, the UK, and key Asia-Pacific markets. This depth of experience will support INBS as it continues advancing its regulatory pathways and prepares for increased commercial activity worldwide.</p>
<div class="lb-trans"><p>Syrma Johari 广泛的监管和质量保证能力进一步与 INBS 的全球扩张计划相一致。它提供端到端的质量体系、监管文档支持和合规流程，旨在满足包括美国、欧洲、加拿大、英国和关键亚太市场在内的主要司法管辖区的要求。这种深厚的经验将支持 INBS 在继续推进其监管路径的同时，为全球商业活动的增加做好准备。</p>
</div><p><em>“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, Vice President of Global Quality and Operations at Intelligent Bio Solutions. “</em> <em>Its</em> <em>global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our Drug Screening Reader. This collaboration strengthens our supply chain, supports future growth, and enhances our ability to deliver reliable, high-quality products to customers around the world.”</em></p>
<div class="lb-trans"><p><em>“与 Syrma Johari 的合作是我们业务的一个战略性重要里程碑，” Intelligent Bio Solutions 全球质量与运营副总裁 Callistus Sequeira 表示。</em> <em>“它的全球足迹、制造卓越和在受监管医疗设备方面的成功记录使其成为我们扩大药物筛查阅读器生产的杰出合作伙伴。这次合作加强了我们的供应链，支持未来的增长，并增强了我们向全球客户提供可靠、高质量产品的能力。”</em></p>
</div><p>Syrma Johari’s leadership shared a similar sentiment, noting that the partnership reflects a strong alignment in innovation, quality, and long-term vision, and that it is pleased to support INBS in scaling a disruptive drug-screening technology with global potential.</p>
<div class="lb-trans"><p>Syrma Johari 的领导层表达了类似的看法，指出此次合作反映了在创新、质量和长期愿景方面的强大一致性，并表示很高兴能够支持 INBS 扩大具有全球潜力的颠覆性药物筛查技术。</p>
</div><p><em>“Partnering with Intelligent Bio Solutions is an exciting opportunity to apply our engineering strength, manufacturing scale, and quality systems to a breakthrough technology with global potential,” said Pankaj Wadke, Head International Sales &amp; Business Development at Syrma Johari MedTech Ltd. “At Syrma Johari MedTech, we are committed to enabling innovative solutions that make a meaningful impact, and we look forward to supporting INBS as they expand access to this disruptive, non-invasive drug-screening platform.”</em></p>
<div class="lb-trans"><p><em>“与 Intelligent Bio Solutions 的合作是一个令人兴奋的机会，可以将我们的工程实力、制造规模和质量体系应用于具有全球潜力的突破性技术，” Syrma Johari MedTech Ltd.国际销售与业务发展负责人 Pankaj Wadke 表示。“在 Syrma Johari MedTech，我们致力于推动创新解决方案，产生有意义的影响，我们期待支持 INBS 扩大对这一颠覆性非侵入性药物筛查平台的访问。”</em></p>
</div><p><strong>About Intelligent Bio Solutions Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Intelligent Bio Solutions Inc.</strong></p>
</div><p>Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.</p>
<div class="lb-trans"><p>Intelligent Bio Solutions Inc.（纳斯达克：INBS）是一家提供智能、快速、非侵入性检测解决方案的医疗技术公司。公司相信，其智能指纹药物筛查系统将通过指纹汗液分析彻底改变便携式检测，具有在其他领域更广泛应用的潜力。该系统设计为卫生且具有成本效益，能够筛查工作场所常见药物的近期使用情况，包括鸦片类药物、可卡因、甲基苯丙胺和大麻。样本收集只需几秒钟，结果在十分钟内即可得出，这项技术将成为安全关键行业雇主的宝贵工具。公司当前在美国以外的客户群体包括建筑、制造和工程、运输和物流公司、矿业、药物治疗组织和法医。</p>
</div><p>For more information, visit: https://ibs.inc/</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://ibs.inc/</p>
</div><p><strong>About Syrma Johari MedTech</strong></p>
<div class="lb-trans"><p><strong>关于 Syrma Johari MedTech</strong></p>
</div><p>Syrma Johari MedTech is a global medical device engineering and manufacturing company with over 45 years of experience delivering advanced electronics, medical devices, and life-science equipment. Operating 14 manufacturing facilities and multiple R&amp;D centres across India, the U.S., and Europe, the company provides end-to-end services spanning design, engineering, prototyping, PCBA, assembly, supply chain, and QARA support. Syrma Johari holds ISO 13485:2016, MDSAP, FDA, GMP, and TUV SUD certifications and has commercialised 245+ medical products worldwide.</p>
<div class="lb-trans"><p>Syrma Johari MedTech 是一家全球医疗设备工程和制造公司，拥有超过 45 年的经验，提供先进的电子产品、医疗设备和生命科学设备。该公司在印度、美国和欧洲运营 14 个制造设施和多个研发中心，提供涵盖设计、工程、原型制作、PCBA、组装、供应链和质量保证与法规支持的端到端服务。Syrma Johari 持有 ISO 13485:2016、MDSAP、FDA、GMP 和 TUV SUD 认证，并在全球范围内商业化了超过 245 种医疗产品。</p>
</div><p>For more information, visit: https://syrmajoharimedtech.com/</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://syrmajoharimedtech.com/</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>
<div class="lb-trans"><p>本公告中的某些声明属于 1933 年证券法第 27A 条、1934 年证券交易法第 21E 条和 1995 年私人证券诉讼改革法的前瞻性声明，涉及风险和不确定性。本新闻稿中的前瞻性声明包括但不限于关于 Intelligent Bio Solutions Inc.成功开发和商业化其药物和诊断测试、从其合作伙伴关系和合作中实现商业利益，以及获得监管批准或许可等方面的声明。尽管 Intelligent Bio Solutions Inc.认为这些前瞻性声明中反映的预期在发布时是合理的，但实际结果可能与这些声明所表达或暗示的结果有重大差异。Intelligent Bio Solutions Inc.试图通过术语来识别前瞻性声明，包括 “相信”、“估计”、“预期”、“期待”、“计划”、“项目”、“打算”、“潜在”、“可能”、“可以”、“或许”、“将”、“应该” 和 “大约” 等，或其他传达未来事件或结果不确定性的词汇来识别这些前瞻性声明。这些声明仅为预测，涉及已知和未知的风险、不确定性和其他因素，包括在 Intelligent Bio Solutions 向美国证券交易委员会的公开文件中描述的因素。本公告中包含的任何前瞻性声明仅在发布之日有效。Intelligent Bio Solutions 没有义务更新本公告中包含的任何前瞻性声明，以反映其日期之后发生的事件或情况，或反映意外事件的发生。</p>
</div><p><strong>Company Contact</strong></p>
<div class="lb-trans"><p><strong>公司联系方式</strong></p>
</div><p>Intelligent Bio Solutions Inc.</p>
<div class="lb-trans"><p>Intelligent Bio Solutions Inc.</p>
</div><p>info@ibs.inc</p>
<div class="lb-trans"><p>info@ibs.inc</p>
</div><p><strong>Investor &amp; Media Contact</strong></p>
<div class="lb-trans"><p><strong>投资者及媒体联系方式</strong></p>
</div><p>Valter Pinto, Managing Director</p>
<div class="lb-trans"><p>Valter Pinto，董事总经理</p>
</div><p>KCSA Strategic Communications</p>
<div class="lb-trans"><p>KCSA 战略传播</p>
</div><p>PH: (212) 896-1254</p>
<div class="lb-trans"><p>电话：（212）896-1254</p>
</div><p>INBS@kcsa.com</p>
<div class="lb-trans"><p>INBS@kcsa.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EUTVNaU0zTXpRd05EVTNJekl4T0RrMU5qVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODQ5MiM3MzQwNDU3IzIxODk1NjU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODUyNGZlMGYtNWI0NS00MzlhLThkOGMtZDZhNTY5YTMzZWRiLTEyMDExMTgtMjAyNS0xMi0zMS1lbg==/tiny/Intelligent-Bio-Solutions-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ODUyNGZlMGYtNWI0NS00MzlhLThkOGMtZDZhNTY5YTMzZWRiLTEyMDExMTgtMjAyNS0xMi0zMS1lbg==/tiny/Intelligent-Bio-Solutions-Inc-.png"/></p>

Intelligent Bio Solutions 宣布与新的制造合作伙伴建立合作，以增强全球生产能力并提高利润率 | INBS 股票新闻